SCHEMBL6442573

SCHEMBL6442573

COc1cc2c(cc1OC)[C@@H]1CCCC[C@@H]1N=C2c1oc2ccccc2c1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.37
KMT2A Q03164 6/20 0.37
NPC1 O15118 2/20 0.37
KDM4E B2RXH2 11/20 0.36
ALDH1A1 P00352 9/20 0.36
HPGD P15428 7/20 0.36
TSHR P16473 4/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
GAA P10253 3/20 0.36
NPSR1 Q6W5P4 2/20 0.36
RAB9A P51151 2/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
ATM Q13315 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM5 P08912 1/20 0.35
CHRM1 P11229 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6442582 1.00 MEN1 (0.37) MEN1KMT2ANPC1KDM4EALDH1A1
SCHEMBL6442578 1.00 MEN1 (0.37) MEN1KMT2ANPC1KDM4EALDH1A1
SCHEMBL6442566 0.79 LMNA (0.39) KMT2AKDM4EALDH1A1HPGDTSHR
SCHEMBL6442559 0.79 LMNA (0.39) KMT2AKDM4EALDH1A1HPGDTSHR
SCHEMBL6442562 0.79 LMNA (0.39) KMT2AKDM4EALDH1A1HPGDTSHR
SCHEMBL6442311 0.78 PDE4D (0.37) MEN1KMT2AKDM4ECHRM1PDE4D
SCHEMBL6442302 0.78 PDE4D (0.37) MEN1KMT2AKDM4ECHRM1PDE4D
SCHEMBL6442306 0.78 PDE4D (0.37) MEN1KMT2AKDM4ECHRM1PDE4D
SCHEMBL2889038 0.75 RAB9A (0.37) MEN1KMT2ANPC1KDM4EALDH1A1
SCHEMBL6445961 0.75 CAMKK1 (0.39) PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303506-B1 6-HETEROARYLPHENANTHRIDINES ALTANA PHARMA AG (DE) 2005-02-02 EP claimed
US-6884802-B2 6-heteroarylphenanthridines ALTANA PHARMA AG (DE) 2005-04-26 US disclosed
EP-1303506-B1 6-HETEROARYLPHENANTHRIDINES ALTANA PHARMA AG (DE) 2005-02-02 EP disclosed
US-20040038979-A1 Treating airway disorders such as asthma. ALTANA PHARMA AG (DE) 2004-02-26 US disclosed
EP-1303506-A1 6-HETEROARYLPHENANTHRIDINES Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2003-04-23 EP disclosed
WO-2002006270-A1 NOVEL 6-HETEROARYLPHENANTHRIDINES ALTANA PHARMA AG (DE) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038979-A1 Treating airway disorders such as asthma. PTGER4, PDE4B, PDE4A MEN1 4313/4885KMT2A 3933/4885NPC1 3880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.